Terazosin hydrochloride dihydrate

SKU: orb1300542

Description

Terazosin hydrochloride dihydrate is a selective α1-adrenoceptor antagonist. It is widely used in pharmacological research, particularly in in vitro binding assays and in vivo models for studying benign prostatic hyperplasia (BPH) and hypertension.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 70024-40-7
• MW: 459.92
• Purity: 99.97%
• Formula: C₁₉H₂₅N₅O₄·HCl·2H₂O
• SMILES: O.O.Cl.COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
• Target: Adrenergic Receptor
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.35 mM);DMSO:25 mg/mL (54.36 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• In Vivo:
  Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 mM, showing that it has a more potent anti-angiogenic than cytotoxic effect. Terazosin also effectively inhibits vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 mM, respectively).
• In Vitro:
  Terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner in prostate cancer cells. Terazosin suppresses prostate growth potentially via α 1-adrenoceptor-independent actions gains further support from another study documenting that Doxazosin inhibits proliferation of human vascular smooth muscle cells independently of an antagonistic effect on α1-adrenoceptor. Terazosin blocks HERG currents in Xenopus oocytes with IC50 of 113.2 mM, while Terazosin blocks HERG channel inhibition in human HEK 293 cells with IC50 of 17.7 mM. Terazosin or genistein treatment inhibits the growth of DU-145 cells in a dose-dependent manner, whereas has no effect on normal prostate epithelial cells. Terazosin results in the genistein-induced arrest of DU-145 cells in G2/M phase being overridden and an increase in apoptotic cells, as evidenced by procaspase-3 activation and PARP cleavage. Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 mM.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AdrenergicReceptor, Adrenergic Receptor, blood, bladder, Dysalfa, Dysalfa Dihydrate, Dysalfa dihydrate, benign, Beta Receptor, Inhibitor, inhibit, Heitrin, Heitrin Dihydrate, Heitrin dihydrate, hyperplasia, high, Flotrin, Flotrin dihydrate, Flotrin Dihydrate, quinazoline, pressure, prostatic, Terazosin HCl, Terazosin HCl Dihydrate, Terazosin Hydrochloride, Terazosin hydrochloride dihydrate, Terazosin hydrochloride Dihydrate, α1-adrenoceptor

Compound Identifiers

PubChem CID

63016